← Eichor
Condition: Her2 Expressing Advanced Solid Tumors Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Her2 Expressing Advanced Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Hutchmed · NCT07228247Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing So
Phase 1 · 7 location(s) · Myeloid Therapeutics · NCT07334119SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
Phase 2 · 1 location(s) · Shenyang Sunshine Pharmaceutical Co., LTD. · NCT07022002Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07512583To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
Phase 2/Phase 3 · 2 location(s) · SUNHO（China）BioPharmaceutical CO., Ltd. · NCT06504732SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors
Phase 2 · 1 location(s) · Shenyang Sunshine Pharmaceutical Co., LTD. · NCT07646626Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Phase 1 · 17 location(s) · SystImmune Inc. · NCT06293898A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
Phase 1/Phase 2 · 15 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT06015048HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors
Phase 1 · 2 location(s) · HighField Biopharmaceuticals Corporation · NCT05861895A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Lo
Phase 1/Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06031584Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for H
Phase 1 · 2 location(s) · National Cancer Institute (NCI) · NCT07137416
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.